HUS1 as a Potential Therapeutic Target in Urothelial Cancer

Area of Science:

• Molecular Oncology
• Cancer Genomics
• DNA Damage Response

Background:

• Platinum-based chemotherapy is standard for metastatic urothelial cancer (UC).
• Chemotherapy resistance in UC is linked to DNA repair mechanisms.
• The Rad9-Rad1-HUS1 complex plays a role in DNA damage response and checkpoint activation.

Purpose of the Study:

• To investigate the role of HUS1 expression in urothelial carcinogenesis.
• To evaluate HUS1 as a potential therapeutic target for predicting platinum-based chemotherapy response in UC.
• To analyze HUS1's influence on cellular proliferation in UC cell lines.

Main Methods:

• Utilized human basal urothelial cancer cell lines (UM-UC-3 and HT1197).
• Achieved specific HUS1 inhibition using small interfering RNA (siRNA) and validated via Western blot.
• Analyzed HUS1's effect on cellular proliferation in cisplatin-treated parental and resistant cells.
• Examined HUS1 expression data from The Cancer Genome Atlas (TCGA) for prognostic significance.

Main Results:

• HUS1 protein was expressed in both UM-UC-3 and HT1197 UC cell lines.
• HUS1 knockdown inhibited proliferation in cisplatin-sensitive cells but did not re-sensitize resistant cells.
• TCGA data revealed HUS1 expression as a significant prognostic factor for poor survival in UC patients.

Conclusions:

• HUS1 may function as an oncogene in urothelial cancer.
• HUS1 expression appears to be a key determinant of cellular response to cisplatin-based chemotherapy.
• HUS1 warrants further investigation as a potential therapeutic target in UC.